PSA decrease during combined-modality radiotherapy predicts for treatment outcome

GJ, Kubicek; M, Naguib; S, Redfield; N, Grayback; A, Olszanski; G, Dawson; SI, Brown

doi:10.1016/j.ijrobp.2009.08.064

Public

PSA decrease during combined-modality radiotherapy predicts for treatment outcome.

Published in International journal of radiation oncology, biology, physics • Feb 18, 2010

NobleIDNI9P43W27R04S19

Authors:

Kubicek GJ

,

Naguib M

,

Redfield S

Abstract

Purpose Prostate-specific antigen (PSA) is the well-used marker in the diagnosis, prognosis, and follow-up for prostate cancer patients. Although reports have focused on the importance of pretreatment PSA levels, doubling time, and posttreatment nadirs, there is little information on the value of PS...

Discussions